[68Ga]Ga-FAPI-46 PET accuracy for cancer imaging with histopathology validation: a single-centre, single-arm, interventional, phase 2 trial
Kim M. Pabst(West German Heart and Vascular Center Essen), Wolfgang P Fendler(German Cancer Research Center), N. von Ostau(German Cancer Research Center), Claudia Kesch(Essen University Hospital), Lukas Kessler(Düsseldorf University Hospital), Lars Erik Podleska(Essen University Hospital), Anke Reinacher‐Schick(Ruhr University Bochum), Martin Schüler(German Cancer Research Center), Manuel Weber(Friedrich-Alexander-Universität Erlangen-Nürnberg), Bastian von Tresckow(University of Cologne), David Kersting(West German Heart and Vascular Center Essen), Sherko Küemmel(Kliniken Essen-Mitte), Patrick Sandach, Jens T. Siveke(German Cancer Research Center), Boris Hadaschik(Essen University Hospital), Rainer Hamacher(Essen University Hospital), Michael Nader(Klinik und Poliklinik für Nuklearmedizin), Markus Eckstein(Friedrich-Alexander-Universität Erlangen-Nürnberg), Christina Laschinsky(Essen University Hospital), Francesco Barbato(German Cancer Research Center), Ken Herrmann(Essen University Hospital), Marija Trajkovic-Arsic(National Center for Tumor Diseases), Timo Bartel(Essen University Hospital), Elena Gilman(Zimmer Biomet (Netherlands)), Viktor Grünwald(Deutsche Schmerzgesellschaft), Hans-Peter Kaelberlah(Lungenklinik Hemer), Alina Küper(German Cancer Research Center)
Cited by 30
Related Papers
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k